48,700 Shares in Certara, Inc. (NASDAQ:CERT) Acquired by Mendel Money Management

Mendel Money Management bought a new stake in Certara, Inc. (NASDAQ:CERT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 48,700 shares of the company’s stock, valued at approximately $519,000.

Several other hedge funds also recently modified their holdings of CERT. Venturi Wealth Management LLC increased its position in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after buying an additional 2,509 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after buying an additional 822 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in Certara by 204.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock worth $58,000 after acquiring an additional 3,656 shares during the period. KBC Group NV boosted its holdings in Certara by 64.1% during the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after acquiring an additional 3,125 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Certara by 442.2% in the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Down 4.3 %

Shares of CERT opened at $10.32 on Wednesday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a 50 day simple moving average of $12.54 and a 200-day simple moving average of $11.47. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.18. The stock has a market cap of $1.66 billion, a PE ratio of -51.60, a PEG ratio of 9.29 and a beta of 1.60.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CERT shares. TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price on the stock. Barclays increased their price target on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Finally, Stephens reiterated an “overweight” rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.